Abstract
The aim of this study was to investigate the new synthetic HMG-CoA reductase inhibitor, fluvastatin, for efficacy, safety and tolerability in comparison to cholestyramine. One hundred fifty one primary hypercholesterolaemic patients participated in this double-blind, parallel-group, randomized study. During the first 12 weeks of the study, fluvastatin (20 mg and 40 mg daily) was compared with cholestyramine (16 g per day). In the subsequent, 6-week part of the study, the comparative efficacy, safety and tolerability of 20 mg fluvastatin, combined with cholestyramine (4 g, 8 g, or 16 g) were assessed.
Fluvastatin (40 mg) reduced LDL cholesterol by 28.0%, triglycerides by 10.5% and increased HDL cholesterol by 3.7%. Cholestyramine (16 g) reduced LDL cholesterol by 35.0%, but raised triglycerides and HDL cholesterol by 12.3% (p<0.01) and 3.7% respectively.
The combination of fluvastatin 20 mg and cholesty-ramine (4 g, 8 g and 16 g) induced the following reductions in LDL cholesterol: 30.4%, 35.6% and 46.6% respectively. There was no significant change in triglycerides in either group although HDL cholesterol was raised by 4.9%, 8.3% and 7.2% respectively. One patient treated with fluvastatin and two treated with cholesty-ramine were withdrawn from the study due to elevation of liver transaminases. The most frequent subjective adverse effects in both treatment groups were mild, transient gastrointestinal complaints.
Thus, fluvastatin was effective as a lipid-lowering agent; the effect was further enhanced when fluvastatin was combined with cholestyramine.
Similar content being viewed by others
References
Stein E, Kreisberg R, Miller V, Mantell G, Washington L, Shapiro DR (1990) Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter group I. Arch Intern Med 150: 341–345
Wiklund O, Angelin B, Fager G, Erikson M, Olofsson SO, Berglund L, Linden T, Sjøberg A, Bondjers G (1990) Treatment of familial hypercholesterolemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 228: 241–247
Hoogerbrugge N, Mol MJ, Van Dormaal JJ, Rustemeijer C, Muls E, Stalenhoef A F, Birkenhager J C (1990) The efficacy and safety of pravastatin, compared to and in combination with bile acid resins in familial hypercholesterolemia. J Intern Med 228: 201–205
Havel RJ, Hunninghake DB, Illingworth DR, Lees S, Stein E, Tobert A, Bacon SR, Bolognese JA, Frost PH, Lamkin GE, Lees AM, Leon AS, Gardner K, Johnson G, Mellies MJ, Rhymer PA, Tun P (1987) Lovastatin (mevinolin) in the treatment of heterozygous hypercholesterolemia. Ann Intern Med 107: 609–615
Lovastatin Study Group II (1986) Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. J Am Med Assoc 256: 2829–2834
Gemershausen JL, Hunt VM, Bostedor RG, Baily PJ, Karkas JD, Alberts JD (1989) Tissue selectivity of the cholesterol lowering agents, lovastatin, simvastatin and pravastatin in rats in vivo Biochem Biophys Res Commun 158: 667–675
Catalano PM, Masonson HN, Newman TJ, Alexander JC (1989) Clinical safety of pravastatin. In: La Rosa JC (ed) Focus on pravastatin. (Royal Society of Medicine Services international congress and symposium series no. 162) Royal Society of Medicine Services Ltd., London, pp 35–38
LaRosa JC (1989) Pravastatin: a new hydrophilic HMG-CoA-reductase inhibitor. In: La Rosa JC(ed) Focus on pravastatin. (Royal Society of Medicine Services international congress and symposium series no. 162) Royal Society of Medicine Services Ltd., London, pp 39–43
Levy RI, Fredricson DS, Stone NJ, Bilheimer DW, Brown VW, Glueck CJ, Gotto AM, Herbert PN, Kwiterovich PO, Langer T, LaRosa J, Lux SE, Rider AK, Schulman AS, Sloan HR (1973) Cholestyramine in type II hyperlipidemia. Ann Intern Med 79: 51–58
Study Group, European Atherosclerosis Society (1988) The recognition and management of hyperlipidemia in adults: a policy statement of the European Atherosclerosis Society. Eur Heart J 9: 571–600
Vu Dac N, Mezdour H, Parra J, Luc G, Luyeye I, Fruchart JC (1989) A selective bi-site immunoenzymatic procedure for human Lp(a) lipoprotein quantification using monoclonal antibodies against apo [a] apo B. J Lipid Res 30: 1437–1443
Lipid Research Clinics Program (1984) The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. J Am Med Assoc 251: 351–364
Einarson K, Ericsson S, Ewerth S, Reihner E, Rudlin M, St»hlberg D, Angelin B (1991) Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol 40 [Suppl 1]: S53-S58
Illingworth D (1991) HMG CoA reductase inhibitor. Curr Opin Lipid 2: 24–30
Arad Y, Ramakrishnan R, Ginsberg HN (1990) Lovastatin therapy reduces low density lipoprotein apo B levels in subjects with combined hyperlipidemia by reducing the production of of apo B-containing lipoproteins: implications for the pathophysiology of apo B production. J Lipid Res 31: 567–582
Malmiender CL, Lonthie JF, Delacroix C, Magot T (1989) Effects of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers. Atherosclerosis 80: 101–109
Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolemia: changes in metabolism of apoprotein B-containing lipoproteins. J Intern Med 227: 81–94
Mabuchi H, Sakai T, Sakay Y, Yoshimura A, Watanabe A, Wakasugi T, Koisumi J, Takeda R (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effect of compactin and cholestyramine. N Engl J Med 308: 609–613
Avogaro P, Bon GB, Cazzolato G, Quinci GB (1979) Are apoproteins better discriminators than lipids for atherosclerosis? Lancet I: 901–903
Ditschuneit HH, Kuhn K, Ditschuneit H (1991) Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 40 [Suppl 1] S27-S32
Levy RI, Troendle A, Fattu JM (1993) Drug treatment of dyslipoproteinemia: a quarter century of progress. Circulation 87 [Suppl III]: III45-III53
Livingstsone MB, Prentice AM, Strain JJ, Coward WA, Black AE, Barker ME, McKenna PG, Withhead RG (1990) Accuracy of weighed dietary records in studies of diet and health. BMJ 300: 1138–1139
Scholler DA (1990) How accurate is self reported dietary energy intake? Nutr Rev 48: 373–379
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hagen, E., Istad, H., Ose, L. et al. Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 46, 445–449 (1994). https://doi.org/10.1007/BF00191909
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00191909